OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

May 9th 2023

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

May 9th 2023

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.

Dr Galsky on the Need for Novel Drug Classes and Non–Cross-Resistant Options in mRCC

May 8th 2023

Matthew Galsky, MD, explains how the development of novel drug classes and therapeutic combinations could address unmet needs in patients with metastatic renal cell carcinoma.

Dr Marshall on Key Takeaways from the 2023 SOGO Annual Meeting in GI Cancer

May 8th 2023

John L. Marshall, MD, discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® and remaining unmet needs for patients with metastatic colorectal cancer.

Dr Habermann on the Evolving Treatment Landscape of Mantle Cell Lymphoma

May 8th 2023

Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr Bal on the Evolution of CAR T-cell Therapy in Multiple Myeloma

May 8th 2023

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer Susceptibility

May 8th 2023

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer

May 8th 2023

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.

Dr Murciano-Goroff on the Evaluation of LY3537982 in KRAS G12C–Mutated NSCLC, CRC and Other Solid Tumors

May 5th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.

Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 5th 2023

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Dr Katz on a Cystoscopic Cryocatheter in Bladder Cancer

May 5th 2023

Aaron E. Katz, MD, discusses the rationale for and findings from a preclinical study evaluating the efficacy of a novel cystoscopic cryocatheter for in situ bladder cancer destruction.

Dr Cole on Race-Based Differences in Prostate Cancer–Specific Mortality

May 5th 2023

Alexander Putnam Cole, MD, discusses findings from a study investigating the effect of type of definitive treatment on race-based differences in prostate cancer–specific mortality in patients with prostate cancer.

Dr Noonan on Challenges Regarding the Sequencing and Selection of Therapies in HCC

May 5th 2023

Anne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options

Dr Das on Updated Data Supporting the Use of Chemoimmunotherapy Regimens in ES-SCLC

May 5th 2023

Devika Das, MD, MSHQS,discusses updated data on the use of immunotherapy and platinum-based chemotherapy regimens in extensive-stage small cell lung cancer.

Dr Sieber on Comorbidities and the Risk of Cardiovascular Events in Prostate Cancer

May 4th 2023

Paul Sieber, MD, discusses the importance of assessing risk factors for cardiovascular events in patients with prostate cancer who are initiating androgen deprivation therapy.

Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer

May 4th 2023

Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600E­mutant mCRC

May 4th 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

Dr Mohan on Toxicities Associated With T-cell–directed Therapy in Myeloma

May 4th 2023

Meera Mohan, MD, MS, FACP, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma.

Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC

May 4th 2023

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.

Dr Patel on How the Timing of ASCT Affects Post-Transplant Complications in Myelofibrosis

May 4th 2023

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

NEXT PAGE
PREVIOUS PAGE